Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion

Key Takeaways

• Sustained revenue and profit growth are driven by successful ORLADEYO performance, new indications, and broader rare disease market expansion.
  
• Enhanced financial flexibility and a strong pipeline position BioCryst for strategic growth through M&A, new product launches, and operational leverage.
  
• Heavy dependence on a single product amid rising competition and reduced geographic reach increases revenue risks, while early-stage pipeline investments heighten financial and execution uncertainties.

Catalysts

A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.

• Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.
  
• Anticipated approval and launch of new indications-such as ORLADEYO granules for pediatric patients and expanded use in HAE with normal C1 inhibitor-broadens the addressable market in an environment of growing global healthcare spending on rare disease therapies, which should further increase long-term revenues and earnings visibility.
  
• Significant financial flexibility from the sale of the European business and accelerated debt paydown sets BioCryst up to deploy capital for pipeline advancement, targeted M&A, or in-licensing, potentially creating additional future revenue streams and supporting stronger net margins.
  
• Progression of a promising pipeline, including programs in Netherton syndrome and DME with expected data readouts by year-end, aligns with advances in molecular diagnostics that improve patient identification-offering potential step-change growth in future revenues and long-term earnings.
  
• Operational leverage from a scalable commercial platform, coupled with the potential to become a consolidator of rare disease assets amid increased M&A activity in biotech, enhances BioCryst's ability to boost operating margins and accelerate earnings growth as new products are integrated.

BioCryst Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming BioCryst Pharmaceuticals's revenue will grow by 11.7% annually over the next 3 years.
• Analysts assume that profit margins will increase from -6.4% today to 27.3% in 3 years time.
• Analysts expect earnings to reach $212.3 million (and earnings per share of $0.92) by about September 2028, up from $-35.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $279.3 million in earnings, and the most bearish expecting $137.5 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 21.2x on those 2028 earnings, up from -48.7x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
• Analysts expect the number of shares outstanding to grow by 1.35% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.31%, as per the Simply Wall St company report.

BioCryst Pharmaceuticals Future Earnings Per Share Growth

Risks

• Heavy reliance on a single product, ORLADEYO, for nearly all current revenue creates significant concentration risk; any negative shifts in market dynamics, competition, or product-specific issues could meaningfully depress future revenues and net margins.
  
• Rising competition in the hereditary angioedema (HAE) market-including recent approvals of alternative HAE therapies (garadacimab, Ekterly, and potential future entrants)-may erode ORLADEYO's market share or limit pricing power, impacting top-line revenue growth and long-term earnings.
  
• The planned divestment of the European business will eliminate a stream of international revenue (especially in Q4 and beyond), increasing dependence on the U.S. market and reducing geographic diversification, possibly constraining future revenue and margin expansion.
  
• Ongoing substantial investment in R&D and business development to build out the pipeline and pursue rare disease asset acquisitions exposes the company to elevated expenses; if these investments do not yield successful commercial products, operating losses and diminished earnings could result.
  
• The pipeline's next wave of assets (Netherton syndrome and DME programs) remain at early clinical stages, facing uncertain timelines and regulatory outcomes; setbacks, delays, or failures could undercut long-term revenue growth prospects and reverse the company's current momentum.

Valuation

• The analysts have a consensus price target of $16.727 for BioCryst Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $11.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $777.6 million, earnings will come to $212.3 million, and it would be trading on a PE ratio of 21.2x, assuming you use a discount rate of 7.3%.
• Given the current share price of $8.29, the analyst price target of $16.73 is 50.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.